Black Diamond Therapeutics, Inc.

Listed Company

BDTXCIK 0001701541NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)FY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$22.37M

Total Assets

$143.01M

Equity

$112.21M

Shares Out

57.30M

Op. Cash Flow

$29.61M

BDTX$1.79−44.32% · past yearDBEQ Basic

Daily closing prices

Business

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's lead program, silevertinib, is a brain-penetrant EGFR inhibitor in Phase 2 trials for EGFR-mutant non-small cell lung cancer and glioblastoma. The company also has an outlicensed RAF inhibitor program (BDTX-4933) licensed to Servier and an early-stage FGFR program. Black Diamond operates in the United States and pursues development through partnerships for pivotal trials and commercialization.

Summary from 10-K filed 2026-03-16

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
License revenue	70	0	—	—	—
Research and development	34	51	59	64	97
General and administrative	17	27	27	28	30
Impairment of right-of-use assets and property and equipment	7	0	—	—	—
Total operating expenses	57	79	86	93	127
Income (loss) from operations	13	−79	−86	−93	−127
Interest income	4	2	2	2	3
Other income (expense)	6	7	2	−354,000	−2
Total other income (expense), net	10	9	4	4	1
Net income (loss)	22	−70	−82	−91	−126
Net income (loss) per share, basic (in dollars per share)	0.39	−1.27	−1.88	−2.52	−3.47
Net income (loss) per share, diluted (in dollars per share)	0.39	−1.27	−1.88	−2.52	−3.47
Weighted average common shares outstanding, basic (in shares)	57	55	44	36	36
Weighted average common share outstanding, diluted (in shares)	58	55	44	36	36
Change in unrealized (loss) gain on investments, net	77,000	51,000	2	−1	−1
Comprehensive income (loss)	22	−70	−81	−93	−127

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	21	36	56	34	66
Investments	108	62	75	88	144
Prepaid expenses and other current assets	4	3	3	5	6
Total current assets	132	101	134	128	216
Property and equipment, net	365,000	1	2	3	3
Restricted cash	829,000	819,000	823,000	1	1
Right-of-use assets	9	19	22	25	28
Other non-current assets	73,000	249,000	0	0	16,000
Total assets	143	123	159	156	248
Accounts payable	579,000	4	2	2	4
Accrued expenses and other current liabilities	15	17	17	13	20
Total current liabilities	16	21	20	15	24
Non-current operating lease liability	15	19	22	25	28
Total liabilities	31	39	42	41	52
Commitments and contingencies (Note 12)	0	0	0	0	0
Preferred stock, $0.0001 par value; 10,000,000 shares and 10,000,000 shares authorized at December 31, 2025 and 2024, respectively; no shares issued or outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock; $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and 500,000,000 shares authorized at December 31, 2024; 57,138,057 shares issued and outstanding at December 31, 2025 and 56,644,655 shares issued and outstanding at December 31, 2024	8,000	7,000	7,000	5,000	5,000
Additional paid-in capital	577	570	534	453	440
Accumulated other comprehensive income (loss)	101,000	24,000	−27,000	−2	−414,000
Accumulated deficit	−465	−487	−417	−335	−244
Total stockholders' equity	112	83	117	116	196
Total liabilities and stockholders' equity	143	123	159	156	248

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	7	11	10	12	14
Depreciation expense	325,000	343,000	437,000	508,000	205,000
(Accretion) amortization on investments	−1	−4	−1	536,000	—
Non-cash rent expense	3	3	3	3	2
Gain on sale of investments	−74,000	0	—	—	—
Gain on sale of property and equipment	−27,000	−94,000	0	—	—
Prepaid expenses and other current assets	−349,000	33,000	2	1	−2
Other non-current assets	176,000	−249,000	0	16,000	90,000
Accounts payable	−3	2	597,000	−2	2
Accrued expenses and other current liabilities	−1	−756,000	4	−6	9
Non-current operating lease liability	−4	−3	−3	−3	−2
Net cash provided by (used in) operating activities	30	−62	−67	−85	−100
Proceeds from disposal of equipment	27,000	94,000	95,000	9,000	0
Proceeds from sales and maturities of investments	119	140	78	114	183
Purchases of investments	−164	−123	−62	−60	−50
Net cash provided by (used in) investing activities	−45	17	16	53	131
Proceeds from exercise of common stock options and ESPP, net of restricted stock surrendered for taxes	−146,000	1	—	—	—
Proceeds from issuance of common stock, net of issuance costs	0	24	72	0	—
Net cash provided by (used in) financing activities	−146,000	26	72	177,000	729,000
Net (decrease) increase in cash and cash equivalents	−15	−20	22	−32	31

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Black Diamond Therapeutics, Inc.'s CIK number?

Black Diamond Therapeutics, Inc.'s SEC CIK number is 0001701541 (1701541). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Black Diamond Therapeutics, Inc.'s SEC filings?

All of Black Diamond Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Black Diamond Therapeutics, Inc. last report earnings?

Black Diamond Therapeutics, Inc. (BDTX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001701541-26-000015). This is Black Diamond Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Black Diamond Therapeutics, Inc.'s most recent earnings 8-K?

Black Diamond Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001701541-26-000015. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Black Diamond Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →